Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E versus ENSKYCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E versus ENSKYCE.
ENOVID-E vs ENSKYCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
ENSKYCE (fospropofol disodium) is a prodrug of propofol. It is hydrolyzed by alkaline phosphatases to release propofol, which acts as a positive allosteric modulator of GABA-A receptors, enhancing chloride conductance and producing sedation and anesthesia.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
2 g IV every 8 hours over 5 hours on days 1-3 of each 21-day cycle
None Documented
None Documented
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
12 hours (terminal); allows once-daily dosing in most patients
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Renal: ~70% unchanged; Biliary/Fecal: ~20% as metabolites
Category C
Category C
Oral Contraceptive
Oral Contraceptive